Eli Lilly’s Retatrutide Yields Up to 70-Pound Loss, Boosts Stock to Record
LLY•Eli Lilly’s investigational weight loss drug retatrutide delivered up to 70 pounds of weight loss in Phase 3 trials with mild-to-moderate side effects, driving the stock to an all-time high. The results strengthen Lilly’s position to dominate the $200 billion obesity treatment market as Zealand Pharma shares tumbled on its own trial setback.
1. Phase 3 Trial Results Exceed Expectations
Retatrutide’s Phase 3 study demonstrated up to 70 pounds of weight loss at the highest dose over the trial period. Participants experienced primarily mild-to-moderate gastrointestinal side effects, with no serious adverse events reported.
2. Market Positioning in Obesity Treatment
These outcomes position Eli Lilly to lead the $200 billion global obesity treatment market, building on its existing diabetes franchise and diversifying revenue streams into weight management.
3. Competitor Setback and Stock Reaction
Shares of Zealand Pharma fell after its own obesity drug trial failed to meet endpoints, while Eli Lilly’s stock surged to a record high as investors reprice growth expectations for the company.
